FindTrial
Sign In

A study to evaluate the usefulness of drug Gabapentin in reducing adverse symptoms after brain injury

Evaluating the role of Gabapentin on incidence and severity of Paroxysmal Sympathetic Hyperactivity in Traumatic Brain Injury: a prospective randomized study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024537
Enrollment
100
Registered
2020-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S062- Diffuse traumatic brain injury Health Condition 2: S062- Diffuse traumatic brain injury

Interventions

Intervention1: Tablet Gabapentin: Tablet Gabapentin in a dose of 300mg BD in patients of traumatic brain injury admitted in icu (safe dose being used in many neurological conditions without any side e

Sponsors

DR SURUCHI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: all patients of traumatic brain injury admitted in icu with age > 18 years and Glasgow coma score of < 13

Exclusion criteria

Exclusion criteria: age pregnancy known allergy to drug known case of renal/hepatic dysfunction

Design outcomes

Primary

MeasureTime frame
based on subjective criteria. no lab parameters studiedTimepoint: three months—

Secondary

MeasureTime frame
to study the effects of gabapention on Glasgow coma scale and Glasgow outcome scale and to study any side effects associated with gabapentinTimepoint: patients will be assessed till 14 days in icu, then at 30th and 90th day. final assessment will be done at 1 year—

Countries

India

Contacts

Public ContactSURUCHI

sgpgi, lucknow

suruchi0904@gmail.com9786025292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026